Patents by Inventor Sonja Offner

Sonja Offner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antibodies against human IL33R and uses thereof
    Patent number: 9309319
    Abstract: An antibody binding to IL33R characterized in that the heavy chain variable domain comprises a CDR3 region of SEQ ID NO:1, a CDR2 region of SEQ ID NO:2 and a CDR1 region of SEQ ID NO:3 and in that the light chain variable domain comprises a CDR3 region of SEQ ID NO:4, a CDR2 region of SEQ ID NO:5 and a CDR1 region of SEQ ID NO:6 or a a chimeric, humanized or T cell epitope depleted antibody variant thereof has advantageous properties for the treatment of inflammatory diseases.
    Type: Grant
    Filed: June 11, 2014
    Date of Patent: April 12, 2016
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Georg Fertig, Jens Fischer, Guy Georges, Klaus Kaluza, Valeria Lifke, Joerg Moelleken, Sonja Offner, Achal Pashine, Stefan Seeber
  • Use of an anti-Tau pS422 antibody for the treatment of brain diseases
    Patent number: 9290567
    Abstract: An antibody binding to Tau that is phosphorylated at serine 422 (pS422), which specifically binds to phosphorylated Tau fragment of SEQ ID NO:9 and to Tau pS422, but does not bind to Tau and to phosphorylated MCAK fragment of SEQ ID NO:17. The antibody is useful in the treatment of a Tauopathy.
    Type: Grant
    Filed: June 6, 2013
    Date of Patent: March 22, 2016
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Bernd Bohrmann, Ulrich Goepfert, Fiona Grueninger, Walter Huber, Hans-Willi Krell, Valeria Lifke, Olaf Mundigl, Sonja Offner, Laurence Ozmen, Michael Schraemi
  • CD40L EXPRESSING MAMMALIAN CELLS AND THEIR USE
    Publication number: 20140315252
    Abstract: Herein is reported a co-cultivation system for co-cultivating a pool of rabbit B-cells or single deposited rabbit B-cells wherein cells CD40L expressing CHO cells are used as feeder in the presence of IL-2 and IL-21.
    Type: Application
    Filed: November 21, 2012
    Publication date: October 23, 2014
    Inventors: Josef Endl, Jens Fischer, Peter Kern, Sonja Offner, Josef Platzer, Stefan Seeber
  • ANTIBODIES AGAINST HUMAN IL33R AND USES THEREOF
    Publication number: 20140302015
    Abstract: An antibody binding to IL33R characterized in that the heavy chain variable domain comprises a CDR3 region of SEQ ID NO:1, a CDR2 region of SEQ ID NO:2 and a CDR1 region of SEQ ID NO:3 and in that the light chain variable domain comprises a CDR3 region of SEQ ID NO:4, a CDR2 region of SEQ ID NO:5 and a CDR1 region of SEQ ID NO:6 or a a chimeric, humanized or T cell epitope depleted antibody variant thereof has advantageous properties for the treatment of inflammatory diseases.
    Type: Application
    Filed: June 11, 2014
    Publication date: October 9, 2014
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Georg Fertig, Jens Fischer, Guy Georges, Klaus Kaluza, Valeria Lifke, Joerg Moelleken, Sonja Offner, Achal Pashine, Stefan Seeber
  • Pharmaceutical composition comprising a bispecific antibody for EpCAM
    Patent number: 8790645
    Abstract: The present invention provides a pharmaceutical composition comprising a bispecific single chain antibody construct. Said bispecific single chain antibody construct is characterized to comprise or consist of at least two domains, whereby one of said at least two domains specifically binds to human EpCAM and comprises at least one CDR-H3 region comprising the amino acid sequence NXID antigen and a second domain binds to human CD3 antigen. The invention further provides a process for the production of the pharmaceutical composition of the invention, a method for the prevention, treatment or amelioration of a tumorous disease and the use of the disclosed bispecific single chain antibody construct and corresponding means in the prevention, treatment or amelioration of a tumorous disease.
    Type: Grant
    Filed: April 4, 2011
    Date of Patent: July 29, 2014
    Assignee: Amgen Research (Munich) GmbH
    Inventors: Peter Kufer, Meera Berry, Sonja Offner, Klaus Brischwein, Andreas Wolf, Tobias Raum, Birgit Kohleisen, Ulla Lenkkeri-Schütz, Patrick Bauerle
  • Antibodies against human IL33R and uses thereof
    Patent number: 8785153
    Abstract: An antibody binding to IL33R characterized in that the heavy chain variable domain comprises a CDR3 region of SEQ ID NO:1, a CDR2 region of SEQ ID NO:2 and a CDR1 region of SEQ ID NO:3 and in that the light chain variable domain comprises a CDR3 region of SEQ ID NO:4, a CDR2 region of SEQ ID NO:5 and a CDR1 region of SEQ ID NO:6 or a chimeric, humanized or T cell epitope depleted antibody variant thereof has advantageous properties for the treatment of inflammatory diseases.
    Type: Grant
    Filed: February 22, 2012
    Date of Patent: July 22, 2014
    Assignee: Hoffmann-La Roche, Inc.
    Inventors: Georg Fertig, Jens Fischer, Guy Georges, Klaus Kaluza, Valeria Lifke, Joerg Moelleken, Sonja Offner, Achal Pashine, Stefan Seeber
  • Use of an anti-Tau pS422 antibody for the treatment of brain diseases
    Patent number: 8609097
    Abstract: An antibody binding to Tau that is phosphorylated at serine 422 (pS422), which specifically binds to phosphorylated Tau fragment of SEQ ID NO:9 and to Tau pS422, but does not bind to Tau and to phosphorylated MCAK fragment of SEQ ID NO:17. The antibody is useful in the treatment of a Tauopathy.
    Type: Grant
    Filed: June 3, 2010
    Date of Patent: December 17, 2013
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Bernd Bohrmann, Ulrich Goepfert, Fiona Grueninger, Walter Huber, Hans-Willi Krell, Valeria Lifke, Olaf Mundigl, Sonja Offner, Laurence Ozmen, Michael Schraeml
  • USE OF AN ANTI-TAU PS422 ANTIBODY FOR THE TREATMENT OF BRAIN DISEASES
    Publication number: 20130310541
    Abstract: An antibody binding to Tau that is phosphorylated at serine 422 (pS422), which specifically binds to phosphorylated Tau fragment of SEQ ID NO:9 and to Tau pS422, but does not bind to Tau and to phosphorylated MCAK fragment of SEQ ID NO:17. The antibody is useful in the treatment of a Tauopathy.
    Type: Application
    Filed: June 6, 2013
    Publication date: November 21, 2013
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Bernd Bohrmann, Ulrich Goepfert, Fiona Grueninger, Walter Huber, Hans-Willi Krell, Valeria Lifke, Olaf Mundigl, Sonja Offner, Laurence Ozmen, Michael Schraemi
  • Antibodies against human IL33R and uses thereof
    Publication number: 20120213774
    Abstract: An antibody binding to IL33R characterized in that the heavy chain variable domain comprises a CDR3 region of SEQ ID NO:1, a CDR2 region of SEQ ID NO:2 and a CDR1 region of SEQ ID NO:3 and in that the light chain variable domain comprises a CDR3 region of SEQ ID NO:4, a CDR2 region of SEQ ID NO:5 and a CDR1 region of SEQ ID NO:6 or a chimeric, humanized or T cell epitope depleted antibody variant thereof has advantageous properties for the treatment of inflammatory diseases.
    Type: Application
    Filed: February 22, 2012
    Publication date: August 23, 2012
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Georg Fertig, Jens Fischer, Guy Georges, Klaus Kaluza, Valeria Lifke, Joerg Moelleken, Sonja Offner, Achal Pashine, Stefan Seeber
  • PHARMACEUTICAL COMPOSITION COMPRISING A BISPECIFIC ANTIBODY FOR EPCAM
    Publication number: 20110256137
    Abstract: The present invention provides a pharmaceutical composition comprising a bispecific single chain antibody construct. Said bispecific single chain antibody construct is characterized to comprise or consist of at least two domains, whereby one of said at least two domains specifically binds to human EpCAM and comprises at least one CDR-H3 region comprising the amino acid sequence NXID antigen and a second domain binds to human CD3 antigen. The invention further provides a process for the production of the pharmaceutical composition of the invention, a method for the prevention, treatment or amelioration of a tumorous disease and the use of the disclosed bispecific single chain antibody construct and corresponding means in the prevention, treatment or amelioration of a tumorous disease.
    Type: Application
    Filed: April 4, 2011
    Publication date: October 20, 2011
    Inventors: Peter Kufer, Meera Berry, Sonja Offner, Klaus Brischwein, Andreas Wolf, Tobias Raum, Birgit Kohleisen, Ulla Lenkkeri-Schutz, Patrick Bauerle
  • Pharmaceutical composition comprising a bispecific antibody for EpCAM
    Patent number: 7919089
    Abstract: The present invention provides a pharmaceutical composition comprising a bispecific single chain antibody construct. Said bispecific single chain antibody construct is characterized to comprise or consist of at least two domains, whereby one of said at least two domains specifically binds to human EpCAM and comprises at least one CDR-H3 region comprising the amino acid sequence NXID antigen and a second domain binds to human CD3 antigen. The invention further provides a process for the production of the pharmaceutical composition of the invention, a method for the prevention, treatment or amelioration of a tumorous disease and the use of the disclosed bispecific single chain antibody construct and corresponding means in the prevention, treatment or amelioration of a tumorous disease.
    Type: Grant
    Filed: May 26, 2004
    Date of Patent: April 5, 2011
    Assignee: Micromet AG
    Inventors: Peter Kufer, Meera Berry, Sonja Offner, Klaus Brischwein, Andreas Wolf, Tobias Raum, Birgit Kohleisen, Ulla Lenkkeri-Schutz, Patrick Baeuerle
  • USE OF AN ANTI-TAU PS422 ANTIBODY FOR THE TREATMENT OF BRAIN DISEASES
    Publication number: 20110059093
    Abstract: An antibody binding to Tau that is phosphorylated at serine 422 (pS422), which specifically binds to phosphorylated Tau fragment of SEQ ID NO:9 and to Tau pS422, but does not bind to Tau and to phosphorylated MCAK fragment of SEQ ID NO:17. The antibody is useful in the treatment of a Tauopathy.
    Type: Application
    Filed: June 3, 2010
    Publication date: March 10, 2011
    Inventors: Bernd Bohrmann, Ulrich Goepfert, Fiona Grueninger, Walter Huber, Hans-Willi Krell, Valeria Lifke, Olaf Mundigl, Sonja Offner, Laurence Ozmen, Michael Schraeml
  • Pharmaceutical composition comprising a bispecific antibody for epcam
    Publication number: 20070081993
    Abstract: The present invention provides a pharmaceutical composition comprising a bispecific single chain antibody construct. Said bispecific single chain antibody construct is characterized to comprise or consist of at least two domains, whereby one of said at least two domains specifically binds to human EpCAM and comprises at least one CDR-H3 region comprising the amino acid sequence NXID antigen and a second domain binds to human CD3 antigen. The invention further provides a process for the production of the pharmaceutical composition of the invention, a method for the prevention, treatment or amelioration of a tumorous disease and the use of the disclosed bispecific single chain antibody construct and corresponding means in the prevention, treatment or amelioration of a tumorous disease.
    Type: Application
    Filed: May 26, 2004
    Publication date: April 12, 2007
    Inventors: Peter Kufer, Meera Berry, Sonja Offner, Klaus Brischwein, Andreas Wolf